Aveanna Healthcare Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Fourteen consecutive quarters of outperformance and strategic acquisitions have driven strong revenue and EBITDA growth, with updated 2026 guidance reflecting recent M&A. Preferred payer and value-based strategies underpin stable, diversified growth, while disciplined financial management supports ongoing de-leveraging and expansion.
-
Q1 2026 saw 15.9% revenue growth and 25.2% adjusted EBITDA growth, driven by preferred payer strategies and operational efficiencies. Guidance for 2026 was raised, and the Family First Homecare acquisition is set to close in late Q2.
-
Year three of strategic transformation delivered strong growth, with 2025 EBITDA reaching $300M and revenue guidance raised. Preferred payer and value-based strategies, successful M&A, and operational modernization underpin 2026 guidance for continued organic growth, margin stability, and disciplined capital deployment.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong double-digit revenue and EBITDA growth, driven by improved rates, higher volumes, and cost efficiencies across all segments. 2026 guidance projects continued organic growth, further expansion of preferred payer agreements, and integration of the Family First acquisition, with leverage expected to remain stable.
-
The conference highlighted strong revenue and EBITDA growth, driven by preferred payer strategies, recent acquisitions, and disciplined cost management. Expansion into new states and continued focus on value-based agreements and M&A are expected to sustain double-digit growth, despite a more muted rate environment ahead.
-
Q3 2025 saw 22.2% revenue growth and 67.5% adjusted EBITDA growth, driven by preferred payer strategies, rate enhancements, and the ThriveSkill Pediatrics acquisition. 2025 guidance was raised, with continued focus on margin expansion, cash flow, and disciplined capital allocation.
-
The business is experiencing strong growth, driven by a transformation strategy, preferred payer partnerships, and recent acquisitions. Financial stability has improved with refinancing and deleveraging, while modernization efforts and cross-selling are set to fuel future expansion. Demand remains robust, with a focus on Medicaid and scalable operations.
-
Q2 2025 saw revenue rise 16.8% to $589.6M and adjusted EBITDA nearly double, driven by rate enhancements, preferred payer strategies, and operational efficiencies. 2025 guidance was raised, with revenue expected above $2.3B and adjusted EBITDA over $270M, including the Thrive acquisition.
-
Focus remains on home-based care and Medicaid stability, with strong early-year rate wins and a growing preferred payer strategy. Clinical innovation and disciplined capital allocation drive growth, while the Thrive acquisition expands reach and integration is underway.
-
Management outlined a robust 2025 strategy focused on expanding scale, preferred payer agreements, and value-based care, with organic growth targets of 5%-7% and M&A expected to push growth above 10%. Q1 saw strong revenue and EBITDA gains, supported by a solid capital structure.
-
Q1 2025 saw 14% revenue growth and a 93% rise in adjusted EBITDA, driven by rate improvements and cost initiatives. Preferred payer agreements and government rate enhancements fueled segment growth, while the Thrive acquisition is set to expand presence and synergies.
-
The conference highlighted ongoing strategic transformation, strong financial performance, and continued margin expansion. Modernization and efficiency efforts are driving growth across all segments, with robust demand, positive cash flow, and a focus on preferred payer partnerships and M&A.
Fiscal Year 2024
-
Q4 and full year 2024 saw strong revenue and EBITDA growth, driven by improved payer rates, cost efficiencies, and expansion of preferred payer agreements. 2025 guidance is prudent, with continued focus on margin expansion, deleveraging, and strategic tuck-in M&A in core segments.
-
Q3 revenue grew 6.5% to $509M and adjusted EBITDA rose 32.2%, driven by payer rate improvements and cost reductions. All segments posted growth, with strong hiring and legislative wins in key states. 2024 revenue is projected at ~$2B, with continued margin normalization and positive cash flow expected.
-
Q2 2024 saw 7% revenue growth and a 27.3% rise in adjusted EBITDA, driven by payer rate improvements and cost controls. Legislative wins in key states and a focus on preferred payer agreements support an enhanced 2024 outlook, despite ongoing labor and seasonal challenges.
-
The organization is accelerating its strategic transformation in 2024, focusing on preferred payer and government affairs strategies to drive growth, secure rate increases, and improve fill rates. Financial targets include $200 million EBITDA by 2026, with stable margins and positive free cash flow supporting M&A and debt reduction.
-
Momentum continues in 2024 as strategic transformation accelerates, driven by preferred payer and government affairs strategies. Material state rate increases are boosting staffing and fill rates, while SG&A efficiencies and stable gross margins support the path to $200 million EBITDA by 2026.